Preparing Patients for Radiation Therapy Side Effects
A study shows that some cancer patients wish they had known more about possible adverse effects of treatment.
Progress Against Cancer
A study shows that some cancer patients wish they had known more about possible adverse effects of treatment.
The FDA has approved a molecularly targeted therapy for epithelioid sarcoma, the first treatment approved for this rare form of soft tissue sarcoma.
The first paper to be accepted by the AACR’s latest journal, Blood Cancer Discovery, was published online last week. The paper, which is freely available on the journal website, describes the landscape of mutations present in pediatric acute lymphoblastic leukemia (ALL) and how this landscape changes during treatment, leading to relapse.
The FDA has approved a molecularly targeted treatment for certain patients with gastrointestinal stromal tumors.
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has metastasized.
The new year began with the good news that death rates from cancer are continuing their steady decline. A study released this week by the American Cancer Society showed that from 2016 to 2017, the most recent year for which statistics are available, the cancer death rate declined by 2.2 percent—the largest single-year decline ever recorded. From 1991 to 2017, the cancer death rate has fallen 29 percent, equaling 2.9 million fewer cancer deaths.
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted therapies.
Around 400 BC, the Greek physician Hippocrates is believed to have first described tumors as “cancer,” using the words “karkinos” or “karkinoma,” which stem from the Greek word for “crab.” Today, the word "cancer" is used to describe hundreds of different types of this disease. As our understanding of cancer continues to grow, prevention, detection, and treatment advancements continue to evolve.
The FDA approved a molecularly targeted therapeutic for patients with advanced or metastatic urothelial cancer.
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More